Allosteric Bioscience, Inc. Licenses Sarcopenia (Muscle Loss) Prevention/Treatment Technology from Johns Hopkins University
Allosteric Bioscience, Inc. (ABI), has announced today that it has licensed technology from Johns Hopkins University for the ...
Jacobs School of Medicine and Biomedical Sciences - University at Buffalo2d
Estrada Receiving Early Career Research Award
The research of D. Fernando Estrada, PhD, associate professor of biochemistry, has been recognized by the American Society for Pharmacology and Experimental Therapeutics (ASPET).
Nanowerk10mon
Enzymes: Biological Catalysts Essential for Life
Enzymes can be regulated by various means, such as allosteric regulation (binding of effector molecules), covalent modification (e.g., phosphorylation), and changes in pH or temperature. The Michaelis ...
Nature1mon
Conformational changes: How small is big enough?
Allosteric effectors that are not competitive can serve as effective activators of weak enzymes or as inhibitors of overactive enzymes. Allosteric activators or inhibitors induce small ...
Hosted on MSN3mon
Proteomics method identifies ligand-binding proteins and binding sites in complex systems
The biochemical functions of proteins invariably involve interactions with ligands of some type, which act as enzyme substrates or inhibitors, signaling molecules, allosteric modulators ...
Business Wire13d
Allosteric Bioscience, Inc. Licenses Sarcopenia (Muscle Loss) Prevention/Treatment Technology from Johns Hopkins University
NEW YORK--(BUSINESS WIRE)--Allosteric Bioscience ... The licensed technology covers the use of inhibitors of an enzyme termed GCPII (glutamate carboxypeptidase II) for the treatment of sarcopenia.